Summary

This article reports on updated study results of an Open-Label Study of Trastuzumab Emtansine versus Capecitabine+Lapatinib in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer [EMILIA; NCT00829166] showing that progression-free survival and overall survival significantly improved in patients with breast cancer treated with trastuzumab emtansine compared with capecitabine plus lapatinib.